首页> 美国卫生研究院文献>British Journal of Cancer >Minichromosome maintenance protein 6 a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma
【2h】

Minichromosome maintenance protein 6 a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

机译:微小染色体维持蛋白6一种优于Ki-67的增殖标志物是套细胞淋巴瘤患者生存的独立预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with a monoclonal antibody against MCM6. The percentage of MCM6 expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (P<0.0001). Surprisingly, the ratio of MCM6-positive cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, P<0.0001). Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL.
机译:微型染色体维持蛋白6(MCM6)是MCM家族的六个蛋白之一,它们参与DNA复制的启动,因此代表了增殖细胞的标志。由于细胞增殖水平是套细胞淋巴瘤(MCL)存活率的最有价值的预测指标,因此我们用抗MCM6单克隆抗体免疫组化研究了70位患者的淋巴结活检标本。表达MCM6的淋巴瘤细胞百分比范围为12.0至95.6%,平均为61.0%,并且显着高于Ki-67阳性细胞百分比(P <0.0001)。出乎意料的是,MCM6阳性细胞与Ki-67阳性细胞的比例高于正常刺激的外周血单核细胞,表明MCL中有早期G1期细胞停滞。与MCL6表达水平低于25%(未达到中位数,P <0.0001)的MCL相比,MCM6表达水平高于75%的阳性细胞的高水平与总体生存时间(16个月)明显缩短有关。多变量分析显示,MCM6是生存的独立预测因子,优于国际预后因素和Ki-67指数。因此,除了基因表达谱分析外,MCM6的免疫组化检测似乎是预测MCL结局的最有希望的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号